Journal of bioinformatics and computational biologyLung NeoplasmsErbB ReceptorsHumansMutationProto-Oncogene Proteins p21(ras)
Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer.
Lanqi Wu, Ruocheng Yu, Minghui Yao, Md Matiur Rahaman, Zhaoyuan Fang
Published: 202510.1142/S0219720025500179
Abstract
Non-small cell lung carcinoma (NSCLC) is well-known for its high incidence (about 80% of lung cancer) and genetic heterogeneity. Personalized driver mutations such as EGFR and KRAS have established targeted therapies with kinase inhibitors, whereas i…
Preview only. Read the full abstract at the source